CGON Stock Summary and Trading Ideas (CG Oncology | NASDAQ:CGON)

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

CG Oncology trades on the NASDAQ stock market under the symbol CGON.

As of March 18, 2026, CGON stock price declined to $65.86 with 978,971 million shares trading.

CGON has a beta of 2.38, meaning it tends to be more sensitive to market movements. CGON has a correlation of 0.31 to the broad based SPY ETF.

CGON has a market cap of $5.44 billion. This is considered a Mid Cap stock.

Last quarter CG Oncology reported $2 million in Revenue and -$.51 earnings per share. This beat revenue expectation by $680,892 and exceeded earnings estimates by $.08.

The top ETF exchange traded funds that CGON belongs to (by Net Assets): VTI, XBI, IWM, VB, VBR.

CGON has outperformed the market in the last year with a price return of +138.0% while the SPY ETF gained +18.9%. CGON has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +76.2% and +8.8%, respectively, while the SPY returned -0.3% and -1.9%, respectively.

CGON support price is $66.09 and resistance is $71.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CGON shares will trade within this expected range on the day.